We support reforms which will allow  all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
National Strategy for High-Cost Drugs for Rare Diseases:
BMC’s Submission to the National Strategy for High-Cost Drugs for Rare Diseases Online Engagement (March 26, 2021)

Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations (July 2019)

Statement Regarding National Pharmacare Interim Report Announcement (March 6, 2019)

Positions and Considerations Regarding National Pharmacare Funding Options (January 2019)

National Pharmacare Implementation: Patient Perspectives and Considerations (September 2018)

BMC Survey:
Patient Perspectives on National Pharmacare: Current Challenges, Goals and Implementation Issues (August 2018)

BMC Positions:
Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)

Submission to the House of Commons Standing Committee on Finance (August 2020)

Pharmacare Position Points (September 2019)

Principles & Considerations Regarding Pharmacare (2016)

Submission: Standing Committee on Health (October 18, 2017)

Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (June 2018) (Français)